Abstract
A comprehensive discussion is presented of the principles underlying the evaluation of safety data from controlled clinical trials. Emphasis is placed on clinical concepts rather than statistical methodology. The essential elements of safety analysis, the critical concepts involved, and trial design issues that affect the interpretation of safety data are explained. Particular attention is paid to the importance of exposure data, the estimation of adverse event frequencies in longer-term trials, evaluation of laboratory data, and the assessment of risk factors.
Similar content being viewed by others
References
International Conference on Harmonization Definitions and Standards for Expedited Reporting. Federal Register. 1998;63:No.10:2396–2404.
White CA. A preliminary assessment of the impact of MEDDRA on adverse event reports and product labeling. Drug Inf J. 1998;32:347–362.
International Conference on Harmonization: Guidance on Statistical Principles for Clinical Trials. Federal Register. 1998;63, No.179:49583–49598.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gait, J.E., Smith, S. & Brown, S.L. Evaluation of Safety Data from Controlled Clinical Trials: The Clinical Principles Explained. Ther Innov Regul Sci 34, 273–287 (2000). https://doi.org/10.1177/009286150003400135
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150003400135